R-CHOP and R-cytarabine for transplant-ineligible MCL

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F25%3A10504566" target="_blank" >RIV/00216208:11110/25:10504566 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/25:10504566
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=NTFaEH3NIA" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=NTFaEH3NIA</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1182/bloodadvances.2025016373" target="_blank" >10.1182/bloodadvances.2025016373</a>

Result language
angličtina
Original language name
R-CHOP and R-cytarabine for transplant-ineligible MCL
Original language description
We read with interest the correspondence by Gutmair et al,1 who did not find major differences between R-CHOP (rituximab, cyclophosphamide, doxorubicin, Oncovin [vincristine], and prednisone) and R-bendamustine in frontline therapy of transplant-ineligible mantle cell lymphoma (MCL). We agree that patients with early progression of disease who were treated with R-CHOP might have an advantage if indicated for T-cell engaging therapies.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)